Nappi Annarita, Di Cicco Emery, Miro Caterina, Cicatiello Annunziata Gaetana, Sagliocchi Serena, Mancino Giuseppina, Ambrosio Raffaele, Luongo Cristina, Di Girolamo Daniela, De Stefano Maria Angela, Porcelli Tommaso, Stornaiuolo Mariano, Dentice Monica
Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.
IRCCS SDN, 80143 Naples, Italy.
Cancers (Basel). 2020 Mar 18;12(3):715. doi: 10.3390/cancers12030715.
Type 2 deiodinase (D2), the principal activator of thyroid hormone (TH) signaling in target tissues, is expressed in cutaneous squamous cell carcinomas (SCCs) during late tumorigenesis, and its repression attenuates the invasiveness and metastatic spread of SCC. Although D2 plays multiple roles in cancer progression, nothing is known about the mechanisms regulating D2 in cancer. To address this issue, we investigated putative upstream regulators of D2 in keratinocyte carcinomas. We found that the expression of D2 in SCC cells is positively regulated by the NANOG transcription factor, whose expression, besides being causally linked to embryonic stemness, is associated with many human cancers. We also found that NANOG binds to the D2 promoter and enhances D2 transcription. Notably, blockage of D2 activity reduced NANOG-induced cell migration as well as the expression of key genes involved in epithelial-mesenchymal transition in SCC cells. In conclusion, our study reveals a link among endogenous endocrine regulators of cancer, thyroid hormone and its activating enzyme, and the NANOG regulator of cancer biology. These findings could provide the basis for the development of TH inhibitors as context-dependent anti-tumor agents.
2型脱碘酶(D2)是靶组织中甲状腺激素(TH)信号传导的主要激活剂,在皮肤鳞状细胞癌(SCC)发生后期表达,其抑制作用可减弱SCC的侵袭性和转移扩散。尽管D2在癌症进展中发挥多种作用,但关于癌症中调节D2的机制尚不清楚。为了解决这个问题,我们研究了角质形成细胞癌中D2的假定上游调节因子。我们发现,SCC细胞中D2的表达受NANOG转录因子的正向调节,NANOG的表达除了与胚胎干性有因果关系外,还与许多人类癌症相关。我们还发现NANOG与D2启动子结合并增强D2转录。值得注意的是,阻断D2活性可降低NANOG诱导的细胞迁移以及SCC细胞中参与上皮-间质转化的关键基因的表达。总之,我们的研究揭示了癌症的内源性内分泌调节因子、甲状腺激素及其激活酶以及癌症生物学的NANOG调节因子之间的联系。这些发现可为开发TH抑制剂作为背景依赖性抗肿瘤药物提供依据。